Use of nifedipine in the treatment of hypertension

References

• Wolf-Maier K, Cooper RS, Kramer H et al. Hypertension treatment and control in five European countries, Canada and the United States. Hypertension43, 10–17 (2004).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. J. Am. Med. Assoc.289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension – European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens.21, 1011–1053 (2003).
   PubMed Web of Science ®Google Scholar
• Neal B, MacMahon S, Chapman N; Blood-Pressure-Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Blood-Pressure-Lowering Treatment Trialists' Collaboration. Lancet356, 1955–1964 (2000).
   PubMed Web of Science ®Google Scholar
• Turnbull F; Blood-Pressure-Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Lancet362, 1527–1535 (2003).
   PubMed Web of Science ®Google Scholar
• Angeli F, Verdecchia P, Reboldi GP et al. Calcium-channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am. J. Hypertens.17, 817–822 (2004).
   PubMed Web of Science ®Google Scholar
• Raemsch KD, Sommer J. Pharmacokinetics and metabolism of nifedipine. Hypertension5, 18–24 (1983).
   Web of Science ®Google Scholar
• Guengerich FP, Martin MV, Beaune PH et al. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem.15, 5051–5060 (1986).
   Google Scholar
• Zanchetti A. Trough and peak effects of a single daily dose of nifedipine gastrointestinal therapeutic system (GITS) as assessed by ambulatory blood pressure monitoring. Italian Nifedipine GITS Study Group. J. Hypertens.2(5) S23–S27 (1994).
   Google Scholar
• Chung M, Reitberg DP, Gaffney M, Singleton W. Clinical pharmacokinetics of nifedipine GITS. A controlled-release formulation of nifedipine. Am. J. Med.83, 10–14 (1987).
   PubMedGoogle Scholar
• Schneider R, Stolero D, Griffel L et al. Pharmacokinetic profile of nifedipine GITS in hypertensive patients with chronic renal impairment. Drugs48(Suppl.), 116–121 (1984).
   Google Scholar
• Krakoff LR. Effectiveness of nifedipine gastrointestinal therapeutic system for treatment of hypertension: results of the MATH trial. J. Cardiovasc. Pharmacol.21, 14–17 (1993).
   Google Scholar
• Toal CB. Efficacy of a low dose nifedipine GITS (20 mg) in patients with mild-to-moderate hypertension. Can. J. Cardiol.13, 921–927 (1997).
   PubMed Web of Science ®Google Scholar
• Houston MC, Olafsson L, Burger MC. Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate and weight in mild-to-moderate hypertension. Angiology42, 681–690 (1991).
   PubMed Web of Science ®Google Scholar
• Leon AS. Efficacy and safety of enalapril versus extended-release nifedipine for the treatment of mild-to-moderate essential hypertension: a multicenter 22-week study. Multicenter Cooperative Study Group. Clin. Ther.15, 1094–1107 (1993).
   PubMed Web of Science ®Google Scholar
• Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet356, 366–372 (2000).
   PubMed Web of Science ®Google Scholar
• Gong L, Zhang W, Zhu Y et al. Shanghai Trial Of Nifedipine in the Elderly (STONE). J. Hypertens.14, 1237–1245 (1996).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L et al. A randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst–Eur) Trial Investigators. Lancet350, 757–764 (1997).
   PubMed Web of Science ®Google Scholar
• Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J. Hypertens.16, 1823–1829 (1998).
   PubMed Web of Science ®Google Scholar
• Mancia G, Brown M, Castaigne A et al. INSIGHT: outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT). Hypertension41, 431–436 (2003).
   PubMed Web of Science ®Google Scholar
• Zusman RM, Christensen DM, Higgins J, Boucher CA. Nifedipine improves left ventricular function in patients with hypertension. J. Cardiovasc. Pharmacol.18, 843–848 (1991).
   PubMed Web of Science ®Google Scholar
• Diamond JA, Krakoff LR, Goldman A et al. Comparison of two calcium blockers on hemodynamics, left ventricular mass and coronary vasodilatory in advanced hypertension. Am. J. Hypertens.14, 231–240 (2001).
   PubMed Web of Science ®Google Scholar
• Zusman RM, Christensen DM, Federman EB et al. Nifedipine, but not propranolol, improves left ventricular systolic and diastolic function in patients with hypertension. Am. J. Cardiol.64, F51–F61 (1989).
   Google Scholar
• Motro M, Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension37, 1410–1413 (2001).
   PubMed Web of Science ®Google Scholar
• Simon A, Gariepy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation19, 2949–2954 (2001).
   Google Scholar
• Zanchetti A, Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J. Hypertens.16, 1667–1676 (1998).
   PubMed Web of Science ®Google Scholar
• Borhani NO, Mercuri M, Borhani PA et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. J. Am. Med. Assoc.276, 785–791 (1996).
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Bond MG, Hennig M et al. European Lacidipine Study on Atherosclerosis Investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation106, 2422–2427 (2002).
   PubMed Web of Science ®Google Scholar
• Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on AntiatherosClerotic Therapy (INTACT). INTACT Group Investigators. Lancet335, 1109–1113 (1990).
   PubMed Web of Science ®Google Scholar
• Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs62, 265–284 (2002).
   PubMed Web of Science ®Google Scholar
• ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation107, 422–428 (2003).
   PubMed Web of Science ®Google Scholar
• McCarthy M. US NIH issues warning on nifedipine. Lancet346, 689–690 (1995).
   PubMed Web of Science ®Google Scholar
• Furberg CD, Psaty BM, Meyer, JV. Nifedipine – dose-related increase in mortality in patients with coronary heart disease. Circulation92, 1326–1331 (1996).
   Google Scholar
• Tijssen JGP, Hugenholtz PG. Critical appraisal of recent studies on nifedipine and other calcium channel blockers in coronary artery disease and hypertension. Eur. Heart J.17, 1152–1157 (1996).
   PubMed Web of Science ®Google Scholar
• Alderman MH, Cohen H, Roque R, Madhavan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet349, 585–586 (1997).
   PubMed Web of Science ®Google Scholar
• Opie LH, Yusuf S, Kubler W. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. Prog. Cardiovasc. Dis.43, 171–196 (2000).
   PubMed Web of Science ®Google Scholar
• Kleinbloesem CH, van Brummelen P, Breimer DD. Nifedipine. Relationship between pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet.12, 12–29 (1987).
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J. Am. Med. Assoc.288, 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Black HR, Elliott WJ, Grandits G et al. CONVINCE Research Group. Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular End points (CONVINCE) trial. J. Am. Med. Assoc.289, 2073–2082 (2003).
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. INVEST Investigators. A calcium antagonist vs. a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The INternational VErapamil–trandolapril STudy (INVEST): a randomized controlled trial. J. Am. Med. Assoc.290, 2805–2816 (2003).
   PubMed Web of Science ®Google Scholar
• Fagan TC, Haggert BE, Liss C. Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension. Clin. Ther.16, 634–646 (1994).
   PubMed Web of Science ®Google Scholar
• Testa MA, Hollenberg NK, Anderson RB et al. Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine gastrointestinal therapeutic system. Am. J. Hypertens.4, 363–373 (1991).
   PubMed Web of Science ®Google Scholar
• Testa MA, Anderson RB, Nackley JF, Hollenberg NK. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group. N. Engl. J. Med.1, 328907–328913 (1993).
   Google Scholar
• Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P. Age and severe adverse drug reactions caused by nifedipine and verapamil. Gruppo Italiano di Farmacovigilanza nell' Anziano (GIFA). J. Clin. Epidemiol.49, 921–928 (1996).
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Lubsen J, Kirwan BA et al. A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system Investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet364, 849–857 (2004).
   PubMed Web of Science ®Google Scholar